India Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

India Breast Cancer Therapeutics Market Analysis

$ 3999

The India breast cancer therapeutics market is witnessing a boost from $331 Mn in 2022 to $1,078 Mn in 2030 with a CAGR of 15.9% for the period 2022-2030 mainly due to increased incidence of breast cancer and novel treatment advances. The market is segmented by therapy, by cancer type and by distribution channel. Key players like Sun Pharmaceutical Industries, AbbVie Inc., and Amgen Inc. are leading companies in the breast cancer therapeutics market.

ID: IN10INPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: India

Buy Now

India Breast Cancer Therapeutics Market Executive Analysis

The India breast cancer therapeutics market size is at around $331 Mn in 2022 and is projected to reach $1,078 Mn in 2030, exhibiting a CAGR of 15.9% during the forecast period. In comparison to the $9.07 Bn in FY 2020–21, the Ministry of Health and Family Welfare received $10.58 Bn from the Union Budget 2022–23, a nearly 16.5 % increase. This rise was caused by increased funding for centrally sponsored public health programs, which are necessary to continue developing sustainable healthcare infrastructure and to maintain system capability to manage the country's rising healthcare needs.

Breast cancer accounts for 14% of cancer cases in Indian women. According to reports, a woman in India receives a breast cancer diagnosis every 4 minutes. Higher stages of cancer growth make survival more challenging, and more than 50% of Indian women have breast cancer that is in stage 3 or stage 4. In India, women with breast cancer reported a 60% post-cancer survival rate, compared to 80% in the US. Mastectomy followed by adjuvant chemotherapy was once a common course of treatment in India for HER2neu-expressing tumours (Human Epidermal Growth Factor Receptor 2), triple-negative breast cancer, and locally advanced breast cancer. Currently, it combines both a systemic therapy method that targets the entire body and a loco-regional approach that uses surgery and radiation therapy to focus exclusively on the tumour.

india breast cancer therapeutics market size

Market Dynamics

Market Growth Drivers

The market is being propelled by an increase in patient support efforts, a strong pipeline of new drugs, and an increase in the incidence of breast cancer along with increasing research and development initiatives in India. The government initiatives like Pradhan Mantri Jan Aarogya Yojana (PMJAY) to cover the hospital expenses of breast cancer patients in India also contribute to the market growth.

Market Restraints

The breast cancer therapeutics market expansion in India is constrained by a number of adjuvant therapy side effects, such as bowel problems and radiation dermatitis, as well as pharmacological adverse responses that raise the risk of chronic and acute effects among breast cancer patients. Another significant barrier is the massive cost of breast cancer therapy in India.

Competitive Landscape

Key Players

Sun Pharmaceutical Industries (IND)
Medion Biotech (IND)
Arvincare (IND)
Globela Pharma (IND)
AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.

Notable Recent Updates

January 2023 - Palbociclib, a breakthrough anti-cancer medicine developed by Sun Pharmaceutical Industries' wholly-owned subsidiaries, has been launched in India for patients with advanced breast cancer. The business will sell the medication under the trade name PALENO.

Healthcare Policies and Regulatory Landscape.

The National Health Mission (NHM) program provides free diagnosis and treatment for breast cancer at government-run hospitals. However, the availability and quality of treatment can vary by region and patients may have to travel to larger cities for advanced treatment. India also has a separate government-funded program called the Rashtriya Arogya Nidhi (RAN), which provides financial assistance for the treatment of breast cancer. This program is intended to help patients who cannot afford the cost of treatment.

Reimbursement Scenario

Patients may be required to pay out-of-pocket for specific treatments or services that are not covered by insurance because there is a lack of uniformity in the rules and reimbursement rates for the treatment of breast cancer throughout India. The type of insurance, the patient's location, and the kind of treatment can all affect the coverage guidelines and reimbursement rates.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.